Background: CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), and dose intensification is a potential strategy for improving therapeutic results. We conducted a phase III trial to determine whether dose-dense strategy involving interval shortening of CHOP (CHOP-14) is superior to CHOP-21.
To determine whether dose-dense chemotherapy involving interval shortening of CHOP is superior to CHOP-21, the Lymphoma Study Group of the Japan Clinical Oncology Group conducted a phase III trial.
patients and methods eligibility criteria
Forty-two centers participated in this trial. Inclusion criteria were as follows: previously untreated intermediate-or high-grade NHL according to the Working Formulation (D through H and J) [11] ; clinical stage II-IV disease (Ann Arbor classification) [12] ; age 15-69 years; Eastern Cooperative Oncology Group performance status 0-2; white blood cell count ‡3.0 · 10 9 /l; absolute neutrophil count (ANC) ‡1.2 · 10 9 /l; platelet count ‡75 · 10 9 /l; aspartate aminotransferase (AST) and alanine aminotransferase levels less than or equal to five times the upper limit of the normal range; total bilirubin level £2.0 mg/dl; serum creatinine level £2.0 mg/dl; PaO 2 ‡65 mmHg; and normal electrocardiogram and cardiac function.
Exclusion criteria included any other malignancy, prior chemotherapy or radiotherapy, central nervous system involvement with lymphoma, HIV infection, positive test for hepatitis B virus surface antigen and/or hepatitis C virus antibody, pregnancy or breast-feeding, severe concomitant disease, or uncontrolled diabetes mellitus.
Written informed consent was obtained from all patients before enrollment, and the protocol was approved by the Protocol Review Committee of Japan Clinical Oncology Group (JCOG) and the Institutional Review Board of each participating center. on day 1, and PDN 100 mg p.o. administered on days 1-5; same dosages of CHOP-14 were administered at every 2 weeks. Patients in the CHOP-14 arm received granulocyte colony-stimulating factor (G-CSF; filgrastim, lenograstim, or nartograstim) on days 6-13 or until their ANC was >10 · 10 9 /l. Patients in the CHOP-21 arm received G-CSF, if necessary. All patients in both study arms received eight courses of chemotherapy except those with progressive disease (PD) after two courses or no response (NR) after four courses when salvage chemotherapy was recommended.
If necessary, after eight courses of chemotherapy, patients were recommended for involved-field radiotherapy (dose 30-50 Gy), if they had initial bulky disease (masses of diameter > 5 cm) or if they only had a partial response (PR) in nonbulky disease.
response assessment
Tumor responses were assessed as per the World Health Organization (WHO) criteria [13] by clinical examination and computed tomography scan after two, four, six, and eight courses of chemotherapy and at 12 weeks after completing chemotherapy or radiotherapy and classified as CR, complete response unconfirmed (CRu), PR, NR, and PD.
statistical methods
All analyses were carried out according to an intent-to-treat principle, using SAS release 9.1 (SAS Institute, Cary, NC). The primary end point was PFS, which was calculated from the date of randomization to that of progression, relapse, or death from any cause. If patients survived without progression, PFS was censored on the latest date when no progression was confirmed. Secondary end points included overall survival (OS) calculated from the date of randomization to the date of death from any cause, CR rate (%CR), and toxicity. PFS and OS curves were generated using the Kaplan-Meier method. Toxicity was assessed as per the JCOG Toxicity Criteria (expanded and modified version of the National Cancer Institute Common Toxicity Criteria, version 1.0) [14] . All patient information forms were collected and managed at the JCOG Data Center where in-house interim monitoring was carried out, and the reports were semiannually reviewed by their Data and Safety Monitoring Committee.
This trial aimed to detect 10% improvement in 5-year PFS rates with CHOP-14 compared with CHOP-21, which was anticipated to have 5-year PFS rate of 50%. This study design required the enrollment of 410 patients with a one-sided a-level of 0.05 to attain 80% power over 4 years of accrual and 7 years of follow-up (including ineligibility and cases lost to follow-up). Two interim analyses were planned. The first involved comparing %CR after half of the patients had been assessed for response. However, blinded in-house monitoring showed poorer PFS than expected; the sample size was then amended to 330 patients, and the end point for the first interim analysis was changed from %CR to PFS.
Superiority of CHOP-14 was assessed by the one-sided log-rank test. Multiplicity was adjusted using an alpha-spending function of the O'BrienFleming type. To summarize the difference between the two arms at interim analysis, hazard ratios (HRs) with confidence intervals (CIs) were calculated [15] . If CHOP-14 proved inferior, the predictive distribution of HR [16] was used to decide whether to stop the trial for futility monitoring. Updated data and estimate HRs between the two arms were analyzed by Cox regression analysis.
central pathology review
Collected biopsy specimens (290 specimens) of enrolled patients were forwarded for central pathology review. Four hematopathologists classified them according to the Working Formulation and WHO classification (third edition) [17] .
results

interim analysis
The first planned interim analysis was carried out in December 2002. Because CHOP-14 was deemed highly unlikely to be superior to CHOP-21 with respect to PFS, the trial was terminated early following recommendations by the JCOG Data and Safety Monitoring Committee on 18 December 2002. At the first interim analysis of 286 patients, median PFS was 33.9 and 24.3 months for patients in CHOP-21 (n = 143) and CHOP-14 (n = 143) arms, respectively (one-sided log-rank P = 0.68). (18, were considered ineligible. After chemotherapy, involved-field radiotherapy (dose 30-50 Gy) was administered to 58 patients (28, with initial bulky disease and 7 with PR and with no initial bulky mass for residual disease (2, .
toxic effects
Collected case report forms of 320 patients (including ineligible patients) were used for evaluating toxic effects (Table 2) . At least one episode of grade 4 neutropenia was experienced by 83.6% and 52.2% patients in CHOP-21 and CHOP-14 arms, respectively. While 12.5% and 20.6% patients in CHOP-21 and CHOP-14 arms, respectively, experienced grade 3 anemia (hemoglobin < 8 g/dl). Only one patient experienced grade 4 thrombocytopenia.
Nonhematologic toxic effects were mild and equivalent in both arms. However, treatment in the CHOP-21 arm was discontinued for four patients [one, decreased left ventricular ejection fraction (<40%); one, hypertension with Wallenberg's syndrome; one, gastric perforation; and one, amebic abscesses in the intestine and liver]. Protocol treatment was discontinued for seven patients (three, pneumonitis; three, ‡grade 2 arrhythmias; and one, a vertebral compression fracture) in the CHOP-14 arm.
After the seventh course of CHOP-14, one patient died suddenly but the cause of death could not be determined. In the CHOP-14 arm, one male patient developed Pneumocystis pneumonia immediately after the eighth course of chemotherapy and died of respiratory failure.
Twenty-nine secondary malignancies cases (CHOP-21 arm: 8 and CHOP-14 arm: 21) were also observed. Median age at lymphoma diagnosis was 59 years (range 32-68 years) and 60 years (range 41-69 years) in CHOP-21 and CHOP-14 arms, respectively. Three and eight patients in CHOP-21 and CHOP-14 arms were >60 years. In the CHOP-21 arm, the cases included non-small-cell lung cancer (n = 1), breast cancer (n = 1), gastric cancer (n = 2), pancreatic cancer (n = 2), prostate cancer (n = 1), and diffuse large B-cell lymphoma (n = 1). Only one pancreatic cancer patient received consolidative radiotherapy. One patient whose lymphoma had progressed during CHOP-21 treatment received allogeneic hematopoietic stem-cell transplantation, and the patient later developed non-small-cell lung cancer. Lymphoma relapse was not observed among other patients. In the CHOP-14 arm, the cases included thyroid cancer (n = 1), non-small-cell lung cancer (n = 2), breast cancer (n = 2), gastric cancer (n = 3), pancreatic cancer (n = 1), colon cancer (n = 3), uterine cervical cancer (n = 1), prostate cancer (n = 1), Ewing's sarcoma (n = 1), mantle cell lymphoma (n = 1), and myelodysplastic syndrome (n = 5). Every patient with breast cancer, mantle cell lymphoma, and colon cancer received consolidative radiotherapy. Lymphoma relapsed in three cases. One patient received salvage and high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation and developed myelodysplastic syndrome 23 months after CHOP-14 treatment. Other patients developed gastric and colon cancer after salvage chemotherapy. Lymphoma relapse was not observed in patients with myelodysplastic syndrome; Toxicity forms collected 320 patients. AST, aspartate aminotransferase; ALT, alanine aminotransferase. they received no additional therapy. In the CHOP-14 arm, the tendency toward development of secondary malignancies, including myelodysplastic syndrome, was significant.
treatment interval and dose intensity
To confirm treatment compliance, we assessed actual treatment duration, course interval, and actual dose administered. Total treatment duration was calculated as the duration from day 1 of the first course to day 1 of the eighth course. The planned duration of CHOP-21 and CHOP-14 treatment were 148 and 99 days, respectively. The relative dose (%) was calculated as the dose actually administered divided by the total dose planned for all eight courses. The course interval was 21 days for 79.3% patients and 14 days for 83.2% patients in CHOP-21 and CHOP-14 arms, respectively. The treatment duration in each arm almost matched the planned duration. Figure 1 shows the distribution of the achievement quotient for planned CPA and DXR doses. In the CHOP-21 arm, median relative doses of CPA and DXR were 97.2% (actual dose range 752-6285 mg per body weight) and 99.4% (actual dose range 50-419 mg/body weight), respectively. In the CHOP-14 arm, median relative doses of CPA and DXR were 98.1% (actual dose range 724-6259 mg/ body weight) and 99.6% (actual dose range 50-411 mg/body weight), respectively. With patients stratified by age (>60 or <60 years), in elderly patients, median relative doses of CPA and DXR were 97.1% and 99.2% in the CHOP-21 arm and were 97.4% and 99.0% in the CHOP-14 arm. In younger patients, median relative doses of CPA and DXR were 97.5% and 99.5% in the CHOP-21 arm and were 98.2% and 99.8% in the CHOP-14 arm. Thus, small variations from the planned course interval and dosage were observed, but compliance was good in both arms.
responses
Responses were assessed 12 weeks after chemotherapy or radiotherapy. Among all randomized patients, CR (including CRu) was observed in 61.5% (95% CI 53.5% to 69.0%) and 66.7% (95% CI 58.8% to 73.9%) patients in CHOP-21 and CHOP-14 arms, respectively (Table 3) . Similar results were observed in eligible patients, and no significant difference was observed between the two arms.
survival Figure 2 shows the PFS and OS curves for all randomized patients. At 7-year follow-up after enrollment termination, no substantial differences were observed in PFS and OS between the two arms. Median PFS was 2.8 and 2.6 in CHOP-21 and CHOP-14 arms, respectively. Eight-year PFS rates were 41.5% (95% CI 33.7% to 49.1%) and 38.4% (95% CI 30.5% to 46.1%) in CHOP-21 and CHOP-14 arms, respectively (P = 0.79, HR original article Annals of Oncology 1.04, 95% CI 0.78% to 1.38%), and 8-year OS rates were 55.9% (95% CI 47.3% to 63.7%) and 55.4% (95% CI 46.9% to 63.0%) in CHOP-21 and CHOP-14 arms, respectively (P = 0.82, HR 1.04, 95% CI 0.75% to 1.45%).
Subgroup analyses were also carried out for risk groups classified as per IPI and for patients stratified in two age groups; no remarkable differences were observed between the two arms for each subgroup (Figure 3 
conclusions
This trial failed to demonstrate the superiority of CHOP-14 over CHOP-21 for the treatment of aggressive NHL. PFS and OS after CHOP-14 were lower than those after CHOP-21 at the first interim analysis, and the trial was terminated early because the estimated predictive probability that CHOP-14 would be significantly superior to CHOP-21 was only 19%, even if the trial was continued. This result did not change even during long-term follow-up.
During treatment, there was no tendency for the interval of CHOP-14 to be postponed. No differences in planned dose and accumulation ratios of key drugs were observed between the two arms, and treatment compliance was not only equivalent but also good in both arms. We therefore do not consider poor compliance, the cause of the lack of difference in efficacy between the two arms. Only 8.4% of the patients had a performance status of 2, and 26% of the patients belonged to high-intermediate and high-risk groups. These values were slightly low, thus implying that more patients with good prognoses were enrolled. However, patient characteristics did not differ completely, and subgroup analysis showed that survival in the high-risk group tended to be equivalent between the two arms. Thus, patient population may not have caused a bias in the study end points.
Other trials using dose-dense chemotherapy have been conducted by two groups. The German High-Grade NonHodgkin Lymphoma Study Group reported that CHOP-14 showed higher event-free survival (EFS) and OS in elderly patients than CHOP-21 in the NHL-B2 trial [18] , and CHOEP-21 (CHOP-21 with etoposide) significantly improved survival compared with CHOP-21 in younger patients with normal lactate dehydrogenase (LDH) in the NHL-B1 trial [19] . As for the difference of these results, Pfreundschuh and Loeffler [20] , in response to Coiffier and Salles [21] , pointed out that the original article Annals of Oncology schedule of CHOP-14 in our trial was well maintained; however, DXR doses were different from those in the NHL-B2 trial. In our trial, 24% patients received <90% of the planned dose of DXR, and 16% of patients received <80%, whereas in the NHL-B2 trial, only 11% and 9% of patients received <90% and 80% of DXR, respectively. Therefore, Pfreundschuh and Loeffler [20] argued that both planned dose and treatment interval must be maintained to preserve the superiority of the two-weekly regimen over the three-weekly regimen. However, results from cumulative dose analyses may differ according to the manner in which cases of early discontinuation of treatment (early off-treatment) are treated. Because relative dose curves in NHL-B1 and -B2 trials do not reflect the early off-treatment rate [18, 19, 22] , Pfreundschuh's argument may not be derived from intention to treat analysis. In our trial, the cumulative percentage of patients receiving <90% of the planned dose of DXR decreases from 20% to 9% if we do not include the early off-treatment rate. Thus, comparison of results using different definitions is irrelevant. In NHL-B1 and -B2 trials, although both total chemotherapy duration and relative dose intensity tended to be better maintained in younger than elderly patients [22] , the dose-dense regimen was not always superior to the 3-weekly regimen for younger patients. Even our trial showed a similar tendency. Moreover, no differences were maintained between our two treatment arms in terms of planned DXR or CPA doses administered or in any other background variable, and comparisons between the treatment arms were reliable.
In exploratory subgroup analysis, unlike in the NHL-B2 trial, CHOP-14 showed no survival advantage for elderly patients and appeared less effective in terms of OS and PFS. The planned CPA and DXR doses for elderly patients were well maintained in CHOP-14 and CHOP-21 arms. Secondary malignancies in elderly patients were observed more often in the CHOP-14 arm, but the cause of death in elderly patients was mostly due to lymphoma in both arms. Consequently, poorer outcomes were not derived from dose reduction of key drugs and secondary malignancies. On the other hand, subgroup analysis indicated that the efficacy of CHOP-14 was slightly greater than that of CHOP-21 in terms of OS and PFS in patients <60 years. In multivariate analysis using Cox regression, elevated LDH was identified as a negative prognostic factor in terms of both PFS and OS (Table 4) . Age-based patient characteristics showed that the number of elderly patients with elevated LDH was greater in the CHOP-14 arm than in the CHOP-21 arm and that of younger patients with elevated LDH was lower in the CHOP-14 arm than in the CHOP-21 arm (Table 5) . Thus, these deviations may have somewhat influenced our results. However, these results were based on a small number of patients and are not statistically significant. In the NHL-B1 trial, CHOP-14 did not exceed CHOP-21 in EFS but slightly exceeded CHOP-21 in OS. Furthermore, the Dutch-Belgian Group conducted a randomized trial comparing Intensified CHOP (I-CHOP), consisting of dose-dense chemotherapy, with CHOP-21, and reported that I-CHOP improved OS in low-intermediate risk patients according to age-adjusted IPI [23] . These results do not show similar tendencies, but taken together, dose-dense chemotherapy may be beneficial for some patients.
Frequency of secondary malignancies in the CHOP-14 arm was also determined in this trial. In the CHOP-14 arm, 9.9% and 3.1% patients developed solid tumors and myelodysplatsic syndrome, respectively, whereas in the CHOP-21 arm, 5.5% patients developed solid tumors and no patient developed myelodysplastic syndrome. Radiation, alkylating agents, and high-dose chemotherapy influence secondary malignancy development, and epipodophyllotoxin, G-CSF, and greater dose intensity are particularly involved with secondary myelodysplastic syndrome and acute myeloid leukemia [24] [25] [26] [27] . Secondary myelodysplastic syndrome development might be greatly affected by G-CSF because such developments were only observed in the CHOP-14 arm. In terms of solid tumors, no differences were observed between the two arms with regard to patient background, such as receiving radiotherapy, dose of alkylating agent, and use of etoposide during or after treatment; thus, preexisting factors are not responsible for these results. Because dose-dense chemotherapy may cause more secondary solid tumors, long-standing careful follow-up of patients is needed.
Our trial did not use rituximab in combination with CHOP because rituximab was unavailable under the Japanese National Health Insurance at the time of patient enrollment. Since the superiority of this combination therapy over CHOP alone has been proven for elderly and younger low-risk patients with diffuse large B-cell lymphoma [28, 29] , it has been recognized as a current standard treatment worldwide. The efficacy of dose-dense chemotherapy combined with rituximab remains yet to be clarified. Delarue et al. [30] recently reported that CHOP-14 was not superior to CHOP-21 plus rituximab in an interim analysis. A similar result was reported by Pfreundschuh et al. [29] , who noted that the benefit achieved with etoposide plus CHOP-21 was absent for CHOP-21 plus rituximab, and he reasoned that this was due to the equalizing effect of rituximab. In the rituximab era, the efficacy of dose-dense chemotherapy may thus not be as significant as before.
Here, CHOP-14 reduced the frequency of febrile neutropenia and shortened the total treatment duration. However, it did not improve survival, was more inconvenient to use, and was significantly more often associated with secondary malignancies. Thus, CHOP-14 is not suitable as a standard regimen to replace CHOP-21, and dose-dense chemotherapy with shortened treatment interval is not useful for improving the outcome in aggressive NHL patients.
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